The Pharmaceutical SOE Holding, Bio Farma Group (including Kimia Farma and Indofarma) is experiencing an overstock of products worth 74 million USD, including vaccines, drugs, and medical devices. However, despite this overstock, customers often experience shortages of their requested products. The Group’s supply chain data is currently neither properly streamed nor uniformly calculated, making it difficult to identify the root cause of the problem.
Any kind of disruption in the supply chain could lead to a domino effect, leading to the unavailability of products downstream.
In Indonesia's e-retailing landscape, no healthcare player is currently offering a comprehensive end-to-end solution. There are still gaps in the business models of existing players; and significant opportunities to optimize sales in existing outlets by improving the supply chain, packaging, and the online-to-offline experience for customers and patients.
Most players currently also do not address the need for continuity of care. Speaking of real case, Kimia Farma Mobile, a mobile application by Kimia Farma, which presently has a strong presence in e-pharmacy retail apparently still lacking and need a lot of improvement in addressing the need for continuity of care. The app also in need of more development on the online-to-offline experience.
24 Agu 2023 - 25 Agu 2023
Biofarma
Jl. Pasteur No.28, Pasteur, Kec. Sukajadi, Kota Bandung, Jawa Barat 40161, Indonesia
$18,000
